Our Research

The national medical cannabis program (Cannabis for Medicinal Purposes and Research (CMPR)) has given Israel a head start in conducting research and developing products and processes around cannabis. Israel’s pharmaceutical ecosystem, together with the Israeli government’s approval of medical cannabis research, facilitates cannabis research at universities and hospitals.

 

Israel is an approved and recognized site for clinical trials and has implemented Israel Medical Cannabis (IMC) Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP) through the U.S.-Israel Science and Technology Commission (USISTC). Phytocannabinoids research for clinical trials is supported in Israel.

CLINICAL TRIALS

$

BOL is positioned to become a leader in cannabinoid pharmaceutical drug development with a comprehensive cannabinoid clinical trial portfolio of 34 phase IIa randomized, double-blind, placebo-controlled trials.

$

Israel is an approved and recognized site for clinical trials and has implemented Israel Medical Cannabis (IMC) – Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP) through the USA – Israel Science and Technology Commission (USISTC).

$

Expansion to new overseas markets and into new medical indications: BOL takes its product portfolio into clinical trials. This enables the penetration of global markets which require clinical trials as a prerequisite for commercialization, opens new medical indications and differentiates our product portfolio.

DRUG DEVELOPMENT

$

Engages in collaborations with universities, academic and medical institutions to develop novel drugs in a range of therapeutic areas.

$

Comprehensive cannabinoid clinical trial portfolio comprising 34 Phase IIa trials.

$

Filed key patents for new innovative drug formulations and drug delivery systems.

DRUG DELIVERY SYSTEM

$

BOL Pharma has exclusive licences to incorporate patented drug delivery technologies in our products, including advanced formulations that enhance absorption and improve dosing and shelf stability.

$

BOL Pharma has developed dosage form capabilities for use in the medical cannabis, health and wellness and pharmaceutical markets. Forms include: medicated drops, sublingual tablets, capsules, metered dose inhalers, topical creams, ocular solutions, reconstituted oral emulsions, and injectables.

POSITIVE INITIAL FEEDBACK FROM AUTISM STUDY

“Every day something amazing happens. For instance, the writing phenomenon. Low functioning autistic children who do not speak usually stay within the refuge of their rooms; There is really no way to communicate with them. Suddenly, parents started reporting that their children are writing. When I saw what they wrote, I couldn’t believe it. Children whose behavioral issues were too severe to be allowed on a school bus, even with a caretaker, suddenly are sitting nicely in their seats.

Dr. Adi Aran

The principle investigator conducting BOLP's Phase || (a) trial on autism, USA TODAY